This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
Subscribe To Our Newsletter & Stay Updated
